(Q30981259)

28 June 2017

1 reference

title

Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review (English)

1 reference

28 June 2017

1 reference

Christopher Eccleston

object named as

Christopher Eccleston

series ordinal

2

0 references

author name string

Rae F Bell

series ordinal

1

1 reference

28 June 2017

Eija Kalso

series ordinal

3

1 reference

28 June 2017

publication date

1 September 2003

1 reference

Journal of Pain and Symptom Management

28 June 2017

published in

1 reference

28 June 2017

volume

26

1 reference

28 June 2017

issue

3

1 reference

28 June 2017

page(s)

867-875

1 reference

Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Low-dose subcutaneous ketamine infusion and morphine tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

How study design affects outcomes in comparisons of therapy. I: Medical

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Subpial vacuolar myelopathy after intrathecal ketamine: report of a case

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Continuous subcutaneous injection of ketamine for cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

High-dose ketamine in the management of cancer-related neuropathic pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Ketamine for cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Successful use of ketamine for central pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Ketamine-fentanyl-midazolam infusion for the control of symptoms in terminal life care

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

[Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture]

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2803%2900311-7

7 January 2021

10.1016/S0885-3924(03)00311-7

Identifiers

DOI

1 reference

28 June 2017

1 reference